New GHX eInvoicing Solution Helps Healthcare Suppliers Meet EU Directives
31.7.2017 09:00 | Business Wire
Global Healthcare Exchange, LLC (GHX) today announced a pan-European eInvoicing solution designed to help healthcare suppliers meet electronic invoicing regulations. With the new GHX eInvoicing, suppliers can issue and send compliant invoices to healthcare provider customers and governments across Europe from one connection.
The GHX solution, which works with the GHX Exchange Services, supports the eInvoicing requirements for integrity, authenticity, legibility and archiving under the VAT Directive 2006/112/ED and the Electronic Invoice Directive 2010/45/EU. It also provides an easy-to-use portal for customers to access invoices electronically, even those with no EDI capabilities.
“Moving away from paper invoices and manual invoicing processes will be an advantage for healthcare suppliers across Europe. However, navigating through the complexity of the European marketplace and complying with the various regulations of the EU member states can be a significant challenge,” said Dr. Nedzad Fajic, president, GHX Europe. “The new GHX eInvoicing solution with its eInvoicing portal will deliver better visibility into the entire order-to-cash cycle, reduce manual processing and help suppliers deliver a better customer experience.”
By November 27, 2018, all EU countries are required to adopt Directive 2014/55/EU into local law, which calls for all invoices sent to hospitals to have ‘authenticity of origin, content integrity and eligibility’ by having business controls and/or electronic invoicing technology in place. GHX eInvoicing is designed to meet those requirements with a simple and efficient solution.
eInvoices will be sent through a supplier’s existing GHX Global Exchange connection and checked to validate content is in the required fields. The eInvoice will then be delivered to the relevant customers and government access points across Europe, with digital signatures and archiving where required for compliance. Non-EDI capable customers will also be able to receive invoices through the new eInvoicing portal, where they can manage and retrieve invoices in PDF format, as well as receive them via email.
The new eInvoicing solution includes:
- Enabling any electronic invoice to be converted in the appropriate format with the appropriate information to comply with EU country-specific invoicing regulations.
- Interoperates with the GHX Global Exchange and other GHX solutions for the full order-to-cash cycle to provide a one-stop solution for eInvoicing in Europe.
- Automatically sends the compliant invoice to the appropriate public administration access point, as well as the appropriate customers.
- A dedicated online portal that allows even non-EDI capable customers to see and download invoices.
- Provides suppliers and their customers with access to current and past invoices all in one place.
- Includes tracking and monitoring capabilities.
GHX eInvoicing is now generally available across Europe. For more information, contact Marcus Schiewe, Head of Supplier Sales, Europe, +49 (0) 211 301 88 300.
About GHX Europe
Global Healthcare Exchange, LLC (GHX), with its European headquarters in Brussels, drives costs out of healthcare with cloud-based supply chain management technology and services to help enable better patient care and savings by maximizing automation, efficiency, and accuracy of business processes. GHX offers European healthcare providers and suppliers an open and neutral electronic trading exchange that delivers procurement and accounts payable automation as well as other supply chain-related tools and services. For more information, visit www.ghx.com/europe/en and The Healthcare Hub.
Tier One Partners
Paula Timko, 508-826-1508
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25 | Tiedote
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00 | Tiedote
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03 | Tiedote
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00 | Tiedote
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08 | Tiedote
Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven
Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00 | Tiedote
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme